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Human native kappa opioid 
receptor functions not predicted 
by recombinant receptors: 
Implications for drug design
John Broad1, Damien Maurel2, Victor W.S. Kung1, Gareth A. Hicks3,†, Michael Schemann4, 
Michael R. Barnes5, Terrence P. Kenakin6, Sébastien Granier2 & Gareth J. Sanger1
If activation of recombinant G protein-coupled receptors in host cells (by drugs or other ligands) has 
predictive value, similar data must be obtained with native receptors naturally expressed in tissues. 
Using mouse and human recombinant κ opioid receptors transfected into a host cell, two selectively-
acting compounds (ICI204448, asimadoline) equi-effectively activated both receptors, assessed by 
measuring two different cell signalling pathways which were equally affected without evidence of 
bias. In mouse intestine, naturally expressing κ receptors within its nervous system, both compounds 
also equi-effectively activated the receptor, inhibiting nerve-mediated muscle contraction. However, 
whereas ICI204448 acted similarly in human intestine, where κ receptors are again expressed 
within its nervous system, asimadoline was inhibitory only at very high concentrations; instead, 
low concentrations of asimadoline reduced the activity of ICI204448. This demonstration of species-
dependence in activation of native, not recombinant κ receptors may be explained by different mouse/
human receptor structures affecting receptor expression and/or interactions with intracellular signalling 
pathways in native environments, to reveal differences in intrinsic efficacy between receptor agonists. 
These results have profound implications in drug design for κ and perhaps other receptors, in terms of 
recombinant-to-native receptor translation, species-dependency and possibly, a need to use human, 
therapeutically-relevant, not surrogate tissues.
There is considerable interest in developing kappa opioid (κ ) receptor agonists to reduce pain, without causing 
dysphoria, addiction or constipation1–4. Drugs which do not cross the blood-brain barrier, for example, retain 
analgesic activity with minimal dysphoria, although intestinal motility remains inhibited2,5. Such drugs may 
treat a diarrhoea-predominant sub-group of patients with irritable bowel syndrome (IBS), a chronic condition 
characterised by abdominal pain and disturbed bowel habit6. Pilot studies with κ receptor agonists (fedotozine7; 
asimadoline8–10) in IBS patients have improved abdominal symptoms, reduced sensitivity to colon distension 
(fedotozine11,12; asimadoline13) and provided adequate relief in a placebo-controlled trial and when given ‘as 
needed’ (asimadoline14,15).
New κ receptor agonists continue to be identified1–4 aided by agonist docking, site-directed mutagenesis and 
crystal structure analysis16. These include functionally-selective κ receptor agonists which induce biased receptor 
signalling1,4, promising drugs which favour a therapeutically-desirable outcome rather than side-effects mediated 
by the same receptor in different tissues17. For approaches which use recombinant receptors in host cells, it is 
essential to translate the proposed activity of a new compound by demonstrating that derived data corresponds 
to the functions of the receptor in its native environment and in particular, for human, therapeutically-relevant 
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tissues. For instance, the existence of cell-specific post-translational modifications of receptor mRNA, altering the 
efficiency of coupling of the receptor to intracellular pathways18,19, would lead to failure of translation.
The need to use human tissues is important because variations in receptor expression, functions and phar-
macology between, for example, rodents and humans, complicates data interpretation and contributes to failed 
translation of novel drug candidates20,21. For the κ receptor, species-dependent variations include the ability of 
agonists to inhibit gastrointestinal (GI) transit of a meal in guinea-pigs and mice, not in rats22. In rats, guinea-pigs 
and pigs, κ receptors are distributed to myenteric neurons within the GI tract which control motility, with little 
expression by submucosal neurons which largely control intestinal secretion23,24, but in mice, the opposite is 
described25. Mouse strain- and species-dependent differences in κ receptor functions within a particular tissue26,27 
creates further uncertainties over which animal best reflects human functions. These include species differences 
in ligand-induced receptor phosphorylation, desensitisation28 and biased agonism (arising from variations in 
receptor structures linked to cell signalling pathways27) and also mouse strain differences in post-translational 
modifications of κ receptor mRNA29.
The present study began by evaluating the abilities of two structurally-distinct κ receptor agonists, ICI20444830 
and asimadoline (EMD 61753)8,9, to inhibit contractions of mouse and human isolated colon evoked by elec-
trical stimulation of intrinsic cholinergic neurons. These contractions represent a function of the main enteric 
excitatory motor neuron of the colon31 and inhibition by opioid receptor agonists reflects at least partly, their 
abilities to reduce diarrhoea or cause constipation32,33. ICI204448 and asimadoline are both described as full or 
maximally-effective agonists at the human κ receptor, with good affinity34–36 and selectivity of action over a range 
of other receptors and ion channels34,36–39. Surprisingly, however, we found marked differences in their abilities 
to reduce cholinergic activity in human colon, whereas both appeared as full agonists in mouse colon40. These 
data prompted a systematic re-examination of the actions of these compounds in a range of different assays using 
recombinant and native κ receptors. Together, the results indicate that the differences in function cannot be 
attributed to variations in potency, biased agonism or functional selectivity for the intracellular Gi protein and 
ß-arrestin signalling pathways. Instead, structural differences between the mouse and human κ receptor may 
affect levels of receptor expression and/or how each receptor orthologue couples to intracellular pathways or 
additional proteins when the receptor is expressed within its native environment, changing the pharmacology of 
the receptor in species-dependent and perhaps, tissue-dependent ways. These data, involving the critical use of 
native human tissue, have clear and profound implications in the design of κ receptor agonists as drugs.
Results
Functional assays using recombinant receptors expressed in host cells. The abilities of asimado-
line and ICI204448 to activate the mouse and human κ receptors were assessed using two different assays of intra-
cellular signalling, examining activation of the G protein (using the Gi alpha subunit, measured using BRET or 
Bioluminescence resonance energy transfer) and internalisation of the receptor into the cell (measured as arrestin 
recruitment, using the BRET assay and κ receptors fused with a YFP at C-terminus).
For both the mouse and human κ receptor, asimadoline and ICI204448 each concentration-dependently 
reduced BRET signalling with similar EC50 values (the concentration which evoked a half-maximal response; 
respectively 0.8 and 0.3 nM for asimadoline and 0.3 and 0.5 nM for ICI204448) and maximum activity 
(Fig. 1A,B; Table 1). In receptor internalisation experiments the effects of asimadoline and ICI204448 were 
first evaluated to determine the internalisation kinetic; all measurements were subsequently made at steady 
state (after 75 min) for dose-responses experiments. Under these conditions, asimadoline and ICI204448 each 
concentration-dependently induced receptor internalisation of both the mouse and human receptors, at similar 
concentrations; the EC50 values were respectively 123 and 55 nM for asimadoline and 50 and 33 nM for ICI204448 
(Fig. 1C,D; Table 2).
Quantification of potential signalling bias. Analysis of the affinity and efficacy of asimadoline and 
ICI204448 in the Gi activation and arrestin recruitment assays for both species showed only minimal evidence 
of biased activity of asimadoline (compared with ICI204448, asimadoline was 1.5 times biased toward producing 
selective Gi activation over receptor internalization; Table 1).
Inhibition of cholinergic activity in mouse colon. In mouse proximal and distal colon, electrical field 
stimulation (EFS) of the intrinsic neurons evoked a small muscle relaxation or sometimes, just inhibition of 
spontaneous contractions and on termination of EFS, a consistent, large-amplitude ‘after-contraction’ (Fig. 2). 
These responses were prevented by the neurotoxin tetrodotoxin 1 μ M (n = 9 and 4, respectively). The presence 
of the muscarinic receptor antagonist atropine 1 μ M, prevented cholinergic activity and revealed or increased 
EFS-evoked relaxations (e.g. by 61 ± 13% in proximal colon; n = 7) and greatly reduced after-contractions (e.g. 
by 81 ± 5% in proximal colon; n = 7). Relaxations were abolished by the nitric oxide synthase inhibitor L-NAME 
300 μ M (n = 4, 3; proximal and distal colon), indicating the involvement of nitric oxide from nitrergic neurons 
and confirming previous observations41. The effects of the κ receptor agonists were then assessed for their ability 
to modulate the larger, more consistent EFS-evoked, cholinergically-mediated after-contractions.
ICI204448 and asimadoline were approximately equi-effective and equi-potent inhibitors of the response 
to EFS with no statistically significant difference between the concentration-response curves for either com-
pound (Fig. 2; Table 3). The Emax (concentration which evoked a maximal response) and EC50 (concentration 
which evoked a half-maximal response) values were determined. In proximal colon the Emax and pEC50 values 
were, respectively, 49 ± 8% and 8.5 ± 0.8 for ICI204448 and 51 ± 8% and 8.1 ± 0.5 for asimadoline. Asimadoline 
had a slower onset of action; the time taken for asimadoline 1 μ M to achieve maximum activity was 17 ± 3 min 
(n = 3) whereas for ICI204448 1 μ M the time to max was 7 ± 2 min (n = 4; P < 0.05). Critically, however, the 
presence of the selective κ receptor antagonist nor-binaltorphamine 300 nM42,43 antagonised the effects of both 
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ICI204448 and asimadoline in mouse proximal colon in a surmountable manner, reducing the calculated pEC50 
values (Fig. 2; Table 3) and confirming that in this assay, ICI204448 and asimadoline acted as κ receptor agonists. 
Both compounds also reduced contractions of the distal colon in a similar manner (e.g. asimadoline 1 μ M and 
ICI204448 1 μ M reduced contractions by, respectively, 59 ± 13% (n = 3) and 70 ± 5% (n = 4). Asimadoline 1 μ M 
and ICI204448 1 μ M had no consistent effects on contractions of proximal colon induced by carbachol 1 μ M 
(respectively: 5 ± 7% (n = 4) and 0 ± 5% (n = 3) initial carbachol response).
Inhibition of cholinergic activity in human colon. Table 4 provides details of the patients from whom 
colon was obtained. As previously reported44, the responses evoked by EFS were prevented by tetrodotoxin 1 μ M 
and were often biphasic. During EFS an initial contraction was observed in most strips of ascending (189/280 
strips studied) and descending colon (351/462), with the remainder displaying relaxation. The contractions 
were prevented by atropine 1 μ M (n = 3 ascending, 6 descending) and when relaxations were observed, these 
were prevented by L-NAME 300 μ M (in 63 strips from 24 ascending colon specimens and 81 strips from 28 
descending colons). These tissues now contracted during EFS; in 3 further experiments the contractions were 
abolished by atropine 1 μ M. After termination of EFS 59% of all strips from ascending colon (observed in 30/32 
patients) contracted (the ‘after-contraction’). Similarly, after-contractions were observed in 92% of strips from 
descending colon (43/43 patients). These contractions have previously been shown to be attenuated by atro-
pine 1 μ M (56 ± 12%, n = 3) but further reduced by application of antagonists at NK1, NK2 and NK3 receptors 
(34 ± 19%, data from44), indicating a small involvement of tachykinergic neurons in the overall response to EFS; 
a residual non-cholinergic non-tachykinergic component was observed on occasion (data not shown). In the 
following experiments with κ receptor agonists the effects were analysed by measuring changes in amplitude 
of contractions during EFS since these contractions were regular in amplitude during repeated stimulation, 
cholinergically-mediated (completely blocked by atropine) and were inhibited by the κ receptor agonists in a 
more consistent manner than the after-contractions (data not shown).
Figure 1. Gi activation and internalisation of κ receptors by asimadoline and ICI204448 in HEK293 cells expressing 
human (panels A and C) and mouse (panels B and D) κ receptors. Gi activation (panels A and B) was measured 
as Gi heterotrimer complex dissociation/conformational changes using bioluminescence resonance energy 
transfer (BRET), calculated by the ratio of emission of Venus (535 nm) to Rluc8 (480 nm) (mBRET). Receptor 
internalization (panels C and D) was monitored by Time-Resolved Fluorescence Energy Transfer (TR-FRET) at 
37 °C, calculated as the ratio of emission of terbium cryptate (620 nm) to fluorescein (520 nm). Concentration-
response curves for asimadoline and ICI204448 were obtained by measuring at steady state (80 min). For each 
receptor, three independent experiments were conducted for asimadoline and ICI204448, and the effects calculated 
as % inhibition of mBRET (Gi activation) measured at the lowest concentrations tested (normalised as 100%) and as 
% increase in TR-FRET ratio (internalisation) and the results expressed as means ± SD.
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ICI204448 and asimadoline each inhibited the EFS-evoked contractions but overall, there was a statisti-
cally significant difference between the concentration-response curves for these compounds (Fig. 3; Table 5). 
In ascending colon, this action of asimadoline appeared slowly and at concentrations higher than those for 
ICI204448. For example, the Emax and pEC50 values for ICI204448 were, respectively, 90 ± 15% and 8.9 ± 0.6 and 
the time to maximum inhibition at 1 μ M was 7 ± 1 min. For asimadoline, the Emax and pEC50 values were, respec-
tively, 108 ± 14% and 7.3 ± 0.4 and the time to maximum inhibition at 10 μ M was 30 ± 5 min (n = 5, P = 0.003). 
Similar activity was observed in descending colon (Fig. 3; Table 5).
In further experiments using descending colon, the effect of ICI204448 was unchanged by the presence of the 
adrenoceptor antagonists phentolamine 1 μ M and propranolol 1 μ M (ICI204448 100 nM inhibited EFS-evoked 
contractions by 130 ± 29% EFS; n = 4), which alone had no effect on responses to EFS (2 ± 3% change from base-
line EFS, n = 4); these data indicate an absence of involvement of noradrenaline in the inhibitory activity of the κ 
receptor agonists. During the presence of atropine 1 μ M, ICI204448 100 nM had no effect on relaxations evoked 
by EFS (1 ± 7% change from baseline EFS; n = 3). Neither asimadoline nor ICI204448 changed baseline muscle 
tension in either region of colon (data not shown).
Since nitrergic and cholinergic neurons are stimulated simultaneously by EFS, each influencing the mag-
nitude of response to the other (see above and44), the experiments were repeated in the presence of L-NAME 
300 μ M. In these conditions the ability of ICI204448 to inhibit the larger contractions of colon muscle strips was 
smaller than in the absence of L-NAME but the potency was unchanged and the overall difference between the 
concentration-response curve for ICI204448 and asimadoline remained statistically significant (Fig. 4, Table 5). 
The effects of asimadoline were again slower in onset and inhibitory activity was achieved only at concentra-
tions > 250 times higher than the effective concentrations of ICI204448 (Fig. 4, Table 5). In descending colon 
ICI204448 similarly inhibited the contractions, whereas the effects of asimadoline were achieved at concentra-
tions 100 times greater than the effective concentrations of ICI204448 (Fig. 4, Table 5). In this region of colon, the 
inhibitory effects of ICI204448 were concentration-dependently antagonised by nor-binaltorphamine 3, 30 and 
300 nM (n = 4 each concentration of ICI204448; slope of Schild analysis = 0.53 ± 0.11, intercept = − 9.7; Fig. 4), 
confirming activation of κ receptors by ICI204448.
In separate experiments in which EFS was not applied, ICI204448 100 nM or asimadoline 1 μ M did not affect 
contractions of descending colon evoked by the submaximally-effective concentration (1 μ M) of carbachol 
(respectively, − 9 ± 2%, n = 4; and − 10 ± 9%, n = 4).
Receptor occupancy studies in human colon. For clarity, these experiments were conducted using 
descending colon in the presence of L-NAME 300 μ M. Asimadoline 100 pM–10 μ M or vehicle (0.1% DMSO) was 
added to the bathing solution 30 min before application of an approximately EC80 concentration of ICI204448 
(60 nM). At low concentrations of asimadoline which did not by themselves affect cholinergically-mediated 
Human Mouse
Asimadoline ICI204448 Asimadoline ICI204448
BRET
 pEC50 9.2 ± 0.1 9.6 ± 0.1 8.9 ± 0.1 9.5 ± 0.1
 Emax (%) 98 ± 5 100 ± 3 99 ± 4 90 ± 4
TR-FRET
 pEC50 7.4 ± 0.1 7.7 ± 0.1 7.0 ± 0.1 7.5 ± 0.1
 Emax (%) 97 ± 2 98 ± 2 96 ± 3 92 ± 4
Table 1. The ability of asimadoline and ICI204448 to recruit G proteins (BRET) and internalise (TR-FRET) 
human and mouse κ receptors expressed in HEK293 cells. There were no statistically significant differences  
(P > 0.1) between each measurement when each compound was compared for both the human and mouse 
receptors (n = 3 replicates).
Gi β-arrestin
Agonist Log(max/EC50) Δlog(max/EC50) ΔΔLog(max/EC50) BIAS Δlog(max/EC50) Log(max/EC50) Agonist
Mouse
 ICI204448 9.301 7.301 ICI204448
 Asimadoline 9.097 0.204 − 0.187 0.65 0.391 6.910 Asimadoline
Human
 ICI204448 9.523 7.481 ICI204448
 Asimadoline 9.523 0.000 − 0.222 0.60 0.222 7.260 Asimadoline
Table 2. Quantification of potential bias in the abilities of asimadoline and ICI204448 to recruit the Gi protein 
and internalise human and mouse κ receptors expressed in HEK293 cells. Mathematical modelling generated 
log(t/KA) values, a transduction coefficient representing the affinity and efficacy of asimadoline and ICI204448 for 
either G protein activation or arrestin mobilization, which showed only minimal evidence of biased activity.
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contractions, and also at the higher concentrations which reduced these contractions, the ability of ICI204448 to 
inhibit EFS-evoked contractions was reduced. The maximum inhibition of this response to ICI204448, at concen-
trations of asimadoline which had no effect on the EFS-evoked contractions, was 19 ± 7%. From this, a pIC50 of 
8.8 ± 0.8 was determined (n = 3–4; Fig. 5).
Figure 2. Concentration-dependent inhibition of cholinergically-mediated, EFS-evoked contractions of 
mouse isolated colon muscle loops. Panels A and B show representative trace examples of ICI 204448 (A) and 
asimadoline (B) in the proximal colon. Panels C and D show the effect of pre-incubation of the kappa opioid 
receptor antagonist norbinaltorphimine 300 nM on the concentration response relationship for the inhibition 
of EFS evoked after contractions of ICI 204448 (C) and asimadoline (D). Data are expressed as means ± SEM; 
n = 3–4 each concentration.
Drug (n) Asimadoline (3–4) ICI204448 (3)
Asimadoline + 
300 nM nor BNI (3–4)
ICI204448 + 300 nM 
nor BNI (3–4)
pEC50 8.1 ± 0.5 8.3 ± 0.5 6.8 ± 0.6 7.0 ± 0.8
Emax (%) 52 ± 7 57 ± 7 51 ± 9 44 ± 11
Table 3.  Inhibition by asimadoline and ICI204448 of cholinergically-mediated contractions in mouse 
isolated colon. pEC50 and Emax values are given in the absence and presence of nor-binaltorphamine (nor BNI), 
for which n-values represent numbers of mice or patients studied. Overall, there was no statistically significant 
difference between the concentration-response curves for asimadoline and ICI204448 obtained in the absence 
of BNI (P = 0.51).
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Opioid receptor gene, kappa (OPRK) alignment and tertiary structural analysis. Human, rat 
and mouse OPRK orthologues were aligned using ClustalX (Fig. 6). Amino acid alterations in the third intracel-
lular loop and C-terminus of OPRK were evaluated for potential impact on G-protein coupling, which is known 
to occur particularly at intracellular charged residues (indicated in magenta) in the 3rd Intracellular loop and 
C-terminal region45. In the 3rd Intracellular loop region, Ala308Val is a neutral substitution in rat from an ali-
phatic hydrophobic residue to a tiny hydrophobic residue. In the C-terminal region in rat and mouse, Leu348Ile 
and Ser358Asn are preferred and neutral substitutions respectively, however both are immediately adjacent to 
charged residues, therefore impact on G-protein coupling cannot be excluded. Four residues across a 6 amino 
acid region appear most likely to impact G-protein coupling. These are Tyr369Ser (unpreferred substitution of 
aromatic polar to tiny polar residue), Leu370Met (preferred), Ile373Val (preferred) and Asp374Gly (neutral sub-
stitution of charged polar residue to a tiny hydrophobic residue). Several of the rodent-specific residues in OPRK 
have been evaluated in previous studies and are known to mediate aspects of receptor function (www.phos-
phosite.org/proteinAction.do?id= 3388). McLaughlin et al.46 demonstrated that GRK-mediated phosphorylation 
of serine 369 mediates rat OPRK desensitization and internalization. Schattauer et al.27 also showed that Ser-369 
phosphorylation site in rat OPRK is required for G protein receptor kinase/arrestin-dependent p38 activation, 
but Ser-358 activates p38 MAPK through a phosphorylation and arrestin-dependent mechanism. Human and 
rodent differences at both residues lead to differing p38 activation for some OPRK ligands. Combining all of these 
observations in an examination of a tertiary structure model of OPRK (Supplementary Data 1) demonstrates 
observable differences in the stearic properties of the amino acid residues altered between human and rodents, 
providing further support for functional alteration.
Discussion
The present experiments, using the κ receptor agonists ICI204448 and asimadoline, demonstrate a marked 
ligand- and species-dependent ability to inhibit cholinergically-mediated contractions in mouse and human 
colon. This was surprising as both compounds are reported as full agonists, with good affinity (Ki values of 2.69 
and 0.17 or 0.6 nM) and selectivity of activity (relative to μ and δ receptors and voltage-activated sodium chan-
nels) at the κ receptor (see Introduction)47. Further, the differences in efficacy could not be related to differences 
in rate of onset of activity (slow for asimadoline, relative to ICI204448), since for each compound this was similar 
in both species; the reason for the differences in onset of activity is unknown although one explanation might be 
a difference in the rate at which each compound diffuses into the tissue. Regardless, additional experiments were 
initiated to understand the ligand- and species-dependent differences in efficacy.
In the proximal and distal mouse colon ICI204448 and asimadoline behaved similarly, inhibiting choliner-
gic activity by acting at the κ receptor (responses in proximal colon were antagonised by the selective κ recep-
tor antagonist nor-binaltorphamine, at a concentration consistent with the range of concentrations reported 
to antagonise at this receptor48), probably by reducing ACh release from intrinsic cholinergic motor neurons 








Ascending 32 (280) 69 (42–89) 1 : 3 189 91 164
Descending 43 (462) 63 (35–90) 1 : 0.9 351 111 424
Table 4.  Experiments with human colon. 1. Patient demographics and summary of responses to electrical 





ICI204448 (4) 100 
pM–1 μM
L-NAME + asimadoline (4) 100 
pM–10 μM
L-NAME + ICI204448 
(4) 100 pM–1 μM
pEC50 7.3 ± 0.4 8.9 ± 0.6 6.4 ± 0.5 8.8 ± 0.3





ICI204448 (4) 100 
pM–1 μM
L-NAME + asimadoline (4–6) 100 
pM–10 μM
L-NAME + ICI204448 
(4–6) 100 pM–1 μM
pEC50 7.1 ± 0.5 8.0 ± 0.4 6.0 ± 0.3 8.0 ± 0.4
Emax (%) 65 ± 11 108 ± 16 56 ± 11 57 ± 7
Table 5.  Experiments with human colon. 2. Inhibition by asimadoline and ICI204448 of cholinergically-
mediated contractions in human ascending and descending colon. pEC50 and Emax values are given in the 
absence and presence of L-NAME (300 µM), for which n-values represent numbers of patients studied.  
Overall, there was a statistically-significant difference in the concentration-response curves for asimadoline 
and ICI204448 in the absence of L-NAME (ascending P = 0.023, descending P = 0.003) and in the presence of 
L-NAME (P < 0.0001 for both regions).
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(contractions evoked by a submaximally-effective concentration of carbachol were unaffected). The efficacy and 
nM potency of both compounds were similar to each other in both regions of colon, and similar pEC50 values 
were calculated from the data. Within the limits naturally imposed by the use of very different assay techniques, 
these pEC50 values were also broadly consistent with the nM concentrations reported as EC50 values in the present 
experiments measuring Gi activation in HEK293 cells expressing the mouse receptor (respectively 0.3 and 0.8 nM 
for ICI204448 and asimadoline) and with experiments by others using radioligand binding assays (IC50’s of 5.6 
and 13 nM, respectively, in guinea-pig cerebellum and 6.6 nM for ICI204448 using mouse κ receptors in COS-1 
cells8,9,49) and functional studies with different animal tissues (EC50’s of 54.5 and 15 nM, respectively, in rabbit vas 
deferens where both compounds behaved as full agonists8,9). Small differences in nM concentrations between 
each of these assays most likely reflect experimental conditions, such as the need for ligands to access receptors in 
cells or intact tissues, or act against different backgrounds of cell/tissue activity. These data are also consistent with 
previous observations in which different κ receptor agonists were found to inhibit cholinergic neuromuscular 
transmission and motility in various animal isolated intestine preparations, indicative of their abilities to reduce 
intestinal motility in vivo (guinea-pig22,50–51; rat53; dog7). Interestingly, in the mouse colon nor-binaltorphamine 
did not by itself change the response to EFS, indicating a lack of activity of endogenous opioids at the κ receptor; 
these data contrast with reported actions of κ receptor antagonists in similar studies using guinea-pig colon, sug-
gesting potential species-dependency in how endogenous opioids affect bowel functions33,51,54.
In experiments measuring Gi activation in HEK293 cells expressing the human κ receptor, ICI204448 
and asimadoline were approximately equi-potent and appeared to act as full agonists, relative to each 
other. However, whereas in human ascending and descending colon low concentrations of ICI204448 
Figure 3. Concentration-dependent inhibition of EFS-evoked contractions of human isolated colon. Panels 
A and B show representative trace examples of ICI 204448 (A) and asimadoline (B). Note the slow onset of 
activity of asimadoline. Panels C,D show concentration response relationships for the inhibition of contractions 
during EFS by ICI204448 and asimadoline in ascending (C) and descending (D) human colon muscle strips. 
Data are expressed as means ± SEM; n = 4–5 each concentration.
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inhibited cholinergically-mediated contractions by acting at the κ receptor (the effects were prevented by 
nor-binaltorphamine, which by itself did not affect contractions to EFS) to reduce ACh release (contractions 
evoked by carbachol were unaffected by ICI204448), asimadoline was effective only at high, μ M concentrations. 
For ICI204448, the effective concentrations were broadly similar to the range of nM concentrations which were 
effective in the human and mouse receptor/Gi assays, in the mouse colon (see above) and in various studies 
reported by others using human κ receptor binding or cell-based functional assays (respectively, Ki 2.69 nM 
and EC50’s of 19 and 4.22 nM4,34,35); again, small differences in values are likely to reflect differences in assay 
Figure 4. Inhibition by ICI204448 and asimadoline of cholinergically-mediated, EFS-evoked contractions 
of human isolated colon in the presence of L-NAME 300 μM. Representative trace examples are shown 
for ICI 204448 (panel A) and asimadoline (panel B). The concentration-response relationships for the 
inhibition of contractions by ICI204448 and asimadoline are shown in panel C for the ascending and in panel 
D for descending colon. Panel E shows the effect of pre-incubation of the kappa opioid receptor antagonist 
norbinaltorphimine 3–300 nM on the concentration-response relationship for the inhibition of contractions 
by ICI 2044448 in the descending colon. Panel F shows a linear regression of the relationship between 
log10[norbinaltorphimine] and the dose ratio − 1 (DR-1) of the EC50s of ICI 204448 in the presence of 3–300 nM 
norbinaltorphimine. Data are expressed as means ± SEM; n = 4–6 each concentration or 3–4 each concentration 
in the experiments with norbinaltorphimine.
Figure 5. Receptor occupancy studies in human descending colon. In these experiments, conducted in the 
presence of L-NAME 300 μ M, asimadoline or vehicle was added 30 min before application of an approximately 
EC80 concentration of ICI204448 (60 nM). The inhibition of EFS-evoked contractions caused by asimadoline 
alone (▲ ), before application of ICI204448, is shown alongside the inhibition of contractions caused by ICI204448 
in the presence of asimadoline (⦁). Data are expressed as means ± SEM; n = 3–4, each concentration tested.
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conditions. These data with ICI204448 are also broadly consistent with two similar studies using human colon 
and different κ receptor agonists55,56. In one other study57 the κ receptor agonist fedotozine inconsistently reduced 
ACh released by electrical stimulation of human colon but consistently reduced contractions evoked by ACh. 
However, the marginal selectivity of fedotozine for the κ receptor (∼ 2-fold over other opioid receptors in dog 
intestine7) and additional actions unrelated to the κ receptor58 may explain these anomalous data.
Asimadoline inhibited cholinergically-mediated contractions of human colon only at high concentrations (e.g 
in ascending colon, pEC50 = 7.9), far in excess of those needed to act at the κ receptor in cell-based assays (e.g. EC50 
of 0.3 nM in the present experiments with the human receptor measuring Gi activation, and Ki’s of 0.17 and 0.6 nM 
in other radioligand binding studies35,36) or in the present experiments with mouse colon. Indeed, this small 
inhibition by high concentrations of asimadoline was not always consistent, making it difficult to confirm that 
it was not due to κ receptor activation by attempting to antagonise with nor-binaltorphamine. Nevertheless, it is 
known that at these high concentrations asimadoline can block tetrodotoxin-sensitive Na+ channels (EC50 8.4 μ M 
in rats39), activate μ -opioid receptors (3 μ M in rats8) and block K+ channels in mouse epithelia (IC50 23.7 μ M59), 
each of which could contribute to the observed ability of asimadoline to inhibit cholinergically-mediated contrac-
tions of human colon. These data also suggest a low propensity of asimadoline to cause constipation in humans, 
relative to ICI204448. Notably, asimadoline is reported not to affect colonic transit or postprandial motility in 
normal healthy volunteers (at doses which reduce sensation to colonic distension60) and although diarrhoea 
was reduced in diarrhoea-predominant IBS patients this did not lead to constipation14. Significantly, however, 
in different experimental studies asimadoline reduced the sensation or pain caused by colonic distension12,13,60, 
suggesting that the inability of asimadoline to reduce cholinergic activity in human colon or cause constipation 
in humans is not due to an inability to act as an agonist at the human κ receptor in its native environment when 
expressed by a different type of cell.
Several reasons could explain why asimadoline failed to act as a κ receptor agonist in human colon yet 
behaved as an efficacious agonist in mouse colon. Schattauer et al.27 found that C-terminal amino acids most 
likely involved in coupling to intracellular signalling pathways are not conserved between rat and human κ recep-
tors, arguing that these differences explain rat-human differences in how compounds might internalise the recep-
tor. A similar comparison was therefore made between the mouse and human κ receptors. Similar differences 
were noted including several charge neutralising amino acid substitutions which would be expected to alter the 
Figure 6. Alignment of OPRK orthologues. Human, rat and mouse OPRK orthologues were aligned using 
ClustalX. Amino acid alterations in the third intracellular loop and C-terminus of OPRK were evaluated for potential 
impact on G-protein coupling, which is known to occur particularly at intracellular charged residues (indicated in 
magenta) in the 3rd Intracellular loop and C-terminal region. In the 3rd Intracellular loop region, Ala308Val is a 
neutral substitution in rat from an aliphatic hydrophobic residue to a tiny hydrophobic residue. In the C-terminal 
region in rat and mouse, Leu348Ile and Ser358Asn are preferred and neutral substitutions respectively, however 
both are immediately adjacent to charged residues, therefore impact on G-protein coupling cannot be excluded. 
Four residues across a 6 amino acid region would appear most likely to impact G-protein coupling. The residues 
which include Tyr369Ser (unpreferred substitution of aromatic polar to tiny polar residue), Leu370Met (preferred), 
Ile373Val (preferred), Asp374Gly (neutral substitution of charged polar residue to a tiny hydrophobic residue).
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efficacy of intracellular signalling, for example through G-proteins. These observations are consistent with the 
previous rat studies, indicating commonality in κ receptor structures and functions among these two examples of 
the rodent order, and also providing a possible explanation for the functional data obtained in the present study.
There is potential for G protein-biased μ opioid receptor agonists to exert analgesic activity in mice but with 
reduced ability to cause constipation61. The latter are thought to be more closely associated with ß-arrestin signal-
ling and μ receptor internalization62–64; ß-arrestin-2 has also been shown to co-localise with choline acetyltrans-
ferase, calretinin and μ opioid receptor expression in the myenteric plexus of mouse intestine65. Similarly, δ opioid 
receptor functions may be changed by agonist-specific recruitment of different arrestin isoforms66. Finally, it has 
been hypothesised that κ receptor agonists which poorly activate the arrestin pathway retain analgesic activity but 
have reduced potential to cause dysphoria4. Together, these observations suggest that different functions of the 
opioid receptors could be evoked by biased receptor signalling, arguably contributing to significant differences 
in efficacy profiles between commonly-used μ opioid receptor agonist drugs67. However, links between the κ 
receptor, arrestin signalling and the potential to cause constipation have not previously been investigated. For this 
reason, the effects of ICI204448 and asimadoline on Gi and internalisation pathways (which reflect the level of 
arrestin recruitment) were examined in HEK293 cells transfected with mouse and human κ receptors. Notably, 
both compounds behaved with approximately similar potency and efficacy. Calculations to identify potential bias 
in how these compounds might activate the Gi and internalisation pathways revealed only a small (1.5-fold) bias 
of asimadoline towards Gi activation in both species, relative to the effects of ICI204448. This small difference 
is unlikely to explain the large difference in potency observed between the two compounds in human isolated 
colon. ICI204448 has previously been shown to have only weak propensity for biased activity towards activating 
the human κ receptor arrestin pathway4.
As it was unclear as to whether asimadoline was acting as a partial agonist at the kappa opioid receptor in 
human colon, receptor occupancy studies were performed to look for an ability of asimadoline to antagonise the 
inhibitory activity of ICI204448 in human colon. The results, showing that 30 min pre-incubation with low con-
centrations of asimadoline could reduce the effects of ICI204448, suggest a number of possibilities.
1. When compared with ICI204448, asimadoline may have lower intrinsic activity at the recombinant human 
κ receptor but this might be observed only when the receptor is expressed at low levels in cell-based assays. 
Further experiments are needed to test this idea.
2. In contrast with the mouse colon, enteric cholinergic neurons within human colon may not express spare receptors. 
This would mean that asimadoline could only act as a partial agonist in human colon but the existence of spare 
receptors in the mouse colon would allow this compound to exert greater efficacy (inhibiting cholinergic activity) 
and appear as a full agonist. The use of an irreversible κ receptor antagonist in experiments using mouse colon 
would test this hypothesis. Thus if spare receptors were present, the antagonist should cause surmountable antag-
onism prior to suppression of maximum activity at higher concentrations.
3. Another possibility is that when the κ receptor is expressed naturally in human enteric cholinergic neurons it 
may be poorly coupled to signalling pathways, relative to the receptor expressed in enteric cholinergic neurons 
of the mouse. Thus, differences between full and partial agonists would become apparent. This could be caused 
by variations in charged amino acids at the C-terminus of the mouse and human receptor, perhaps exacerbated 
by post-translational modifications of κ receptor mRNA within different tissues, changing levels of receptor 
coupling and/or expression in a cell-dependent manner and hence, ligand receptor efficacy18,19.
4. Asimadoline could still behave as a full agonist in human cells or tissues in which the functions of the κ  
receptor are not limited by an absence of spare receptors or by poor receptor coupling. This would include 
cells outside the gastrointestinal tract such as those mediating the previously-demonstrated analgesic activity 
of asimadolone13.
5. Although the existence of κ receptor subtypes seems unlikely, given that only one κ receptor cDNA clone has 
been reported and no receptor variants have been identified, it is possible that in the native environment the 
κ receptor could interact with another receptor or protein, changing its pharmacology in a species-dependent 
manner46. This has been demonstrated for the cloned κ receptor which can functionally couple to N-type 
calcium channels68; such couplings may alter the ability of the receptor to recognise the ligand or change the 
ability of the receptor to communicate with intracellular signalling pathways, possibly in a biased manner and 
hence, affect its efficacy17.
Thus in summary, the present experiments demonstrate a marked ligand- and species-dependent difference in 
the efficacy of at least two different κ receptor agonists in human and mouse isolated colon, most likely explained 
by differences in intrinsic activities of the compounds at the receptor revealed by differences in how the receptors 
in their native environments are expressed or coupled to intracellular pathways or other proteins. The extent to 
which different κ receptor agonists replicate the actions of either asimadoline or ICI204448 is unknown (in a 
pilot study with three different κ receptor agonists, characterised by others in cell-based assays, we demonstrated 
approximately similar efficacy as ICI204448 in human isolated intestine; Supplementary Data 2), being dependent 
on the chemical template used and the degree of subsequent structural modification. As such, these data have 
clear and important implications in new drug design for G protein-coupled receptor agonists since they imply 
that false information may be derived by reliance on assays measuring receptor functions in host cells, in animal 
tissues and possibly, in tissues which have little or no human therapeutic importance.
Methods
Functional assays using recombinant receptors expressed in host cells. Using HEK293 cells express-
ing human or mouse κ receptors, concentration-response curves were established in assays for Gi activation (measur-
ing Gi heterotrimer complex dissociation/conformational changes using bioluminescence resonance energy transfer; 
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BRET) and arrestin recruitment (measuring receptor internalization; BRET assay; κ receptors fused with a YFP at 
C-terminus). In all experiments, the cells were grown in DMEM supplemented with 10% FBS at 37 °C, 5% CO2.
For measurement of Gi activation, HEK293 cells were seeded into 96-well white plates at a density of 100,000 
cells per well. The cells were transfected with 4 plasmids encoding the human κ receptor, the Gα i1 protein 
fused to Renilla Luciferase8 (Gα i1-Rluc8: donor) and the β 2 and Venus-γ 2 G protein subunits (provided by the 
ARPEGE platform), at a 1:1:1:1 ratio. Cells were transfected directly into the plate using lipofectamine 2000 rea-
gents as described by the manufacturer (Invitrogen). 24 h after transfection, cells were washed twice with PBS. 
Basal conditions were achieved by the addition of PBS 40 μ l, followed by 10 μ l coelenterazine H (5 μ M total). To 
evaluate the effects of κ receptor ligands, the addition of PBS 30 μ l was followed by addition of 10 μ l coelenterazine 
H (5 μ M total) and then 10 μ l of each concentration of ligand. Activation of the κ receptors promotes dissociation 
of the Gα β γ protein complex resulting in the BRET signal decay. BRET between Rluc8 and Venus was measured 
after addition of the Rluc substrate coelenterazine H (5 μ M). BRET readings were collected using a Mithras 2 
plate reader. The BRET signal was calculated by the ratio of emission of Venus (535 nm) to Rluc8 (480 nm): 
mBRET = {(Ratio 535/480)assay − (Ratio 535/480)Rluc8 alone)} X 1000.
Receptor internalization was monitored by TR-FRET (Time-Resolved FRET). HEK293 cells were transfected 
with one plasmid encoding the SNAP-tagged κ receptor. 24 h after transfection, cells were labelled with 100 nM 
BG-Tb (benzylguanine-Terbium cryptate) for 1 h at 37 °C in DMEM supplemented with 10% FBS. After four 
washing steps with PBS, the fluorescence signal from BG-Tb was measured on an INFINITE F500 (TECAN) 
plate reader with an excitation at 337 nm and emission at 620 nm. After adding 24 μ M fluorescein with increasing 
concentrations of κ receptor ligands, the internalization process was followed at 37 °C during 70–80 min. The 
signal was calculated by the ratio of emission of terbium cryptate (620 nm) to fluorescein (520 nm): Δ R = (Ratio 
620/520) X 10,000.
The procedures for activating the G protein Gi (alpha subunit) were validated by control experiments. Firstly, 
for each experiment mouse and human κ receptor expression on the cell membrane was confirmed (by SNAP-tag 
labelling with BG-Tb); overall, the levels of expression were similar for both receptors (Supplementary Data 3). 
Secondly, non-specific activity of the κ receptor ligands on the BRET (bioluminescence resonance energy trans-
fer) signal was determined using human embryonic kidney cells, type 293 (HEK293), transfected with the Gα 
i1 protein complex alone (no receptor) and exposed to increasing concentrations of ICI204448 and asimadoline 
(Supplementary Data 4). Finally, in each experiment, a negative and positive control was added. For the negative 
control, the vasopressin V2 receptor coupled to Gs was co-transfected with the Gα i1 protein complex and stimulated 
with Arginine-Vasopressin (AVP) (Supplementary Data 5). As a positive control, the μ -opioid receptor coupled to 
Gi was co-transfected with the Gα i1 protein complex and stimulated with DALDA (H-Tyr-D-Arg-Phe-Lys-NH2; 
Supplementary Data 5). Similarly, in each internalisation experiment with the mouse and human receptor, the level 
of SNAP-KOR expression was confirmed and shown to not significantly differ between the two receptors. For each 
experiment the vasopressin V2 receptor was used as a positive control (Supplementary Data 6).
Quantification of potential signalling bia. The concentration-response curves derived from the Gi acti-
vation and arrestin assays were fitted to a mathematical model based on the Black and Leff 69 operational model to 











n 1/n . This value represents the affinity and efficacy of the ligand for G 
protein activation or arrestin mobilization. The model incorporates receptor density and coupling within a system 
and is independent of receptor expression.
Inhibition of cholinergic activity in mouse colon. Adult male C57BLK6/J mice (25–30 g) were culled by 
cervical dislocation followed by confirmation of death by cessation of blood circulation, in accordance with the 
UK Animals (Scientific Procedures) Act 1986. The protocol was approved by the AWERB (Animal welfare ethical 
review board) for Queen Mary University of London and those involved were trained and signed off as competent 
by the Named Training and Competency Officer and Named Animal Care and Welfare Officer. All efforts were 
made to minimise the number of mice used. The proximal and distal regions of colon were blunt-dissected and 
placed in Krebs solution (mmolL−1: NaCl 121.5, CaCl2 2.5, KH2PO4 1.2, KCl 4.7, MgSO4 1.2, NaHCO3 25, glucose 
5.6) equilibrated with 5% CO2 in O2 at room temperature.
Mucosa-intact loops, cut parallel to the circular muscle of the colon were mounted between two platinum 
ring electrodes in 5 ml tissue baths containing Krebs solution at 37 °C and gassed with 5% CO2 in O2. Changes 
in muscle tension were recorded using isometric force transducers (AD Instruments, Chalgrove, UK) on a data 
acquisition system (Biopac Systems Inc., Goleta, CA, USA). The strips were given 1 g tension and allowed to 
recover for 30 min during which time the bath solutions were changed every 15 min; this initial tension was 
previously determined as the optimum required to maximally detect EFS-evoked responses in both regions (data 
not shown). Electrical Field Stimulation (EFS) was applied at 5 Hz using a maximally-effective voltage (80 V) and 
0.5 ms bipolar pulse duration pulse duration, given for 30 s every 120 s, for at least 1 hour before drug addition. 
These parameters of EFS consistently evoked nerve-mediated responses with a good signal-to-noise ratio over 
spontaneous muscle activity. After obtaining consistent responses, drugs were applied non-cumulatively to sepa-
rate tissues (20 min contact); changes in resting muscle tension and responses to EFS were measured. Finally, any 
effects of the drugs on carbachol-induced contractions were examined by first obtaining consistent responses to 
a submaximally-effective concentration of carbachol (1 μ M; 27 ± 9% max, 5 min contact; n = 4). The compounds 
were then added 5 min before application of carbachol (1 μ M, 5 min contact), followed by washing, and this pro-
cess was repeated at least once more.
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Inhibition of cholinergic activity in human colon. Human ascending and descending colon was obtained 
from patients undergoing surgery for bowel cancer without obstruction or inflammatory bowel disease, in accord-
ance with human ethics regulations and protocols approved by the East London Research Ethics Committee 1 
(NREC 09/H0704/2 and 10/H0703/71); written informed consent was obtained from all patients. The tissues were 
removed at least 10 cm from the tumour and were macroscopically normal, approaching a definition of ‘normal’21. 
The specimens were transferred to the research laboratory within 2 h after resection in Krebs solution equilibrated 
with 5% CO2 and 95% O2. Immediately on arrival, the mucosa was removed by blunt dissection and discarded. 
Strips (~5 mm wide, 12 mm long) were cut parallel to the circular muscle fibres from the inter-taenia region of each 
colon and were used immediately or after overnight storage at 4 °C in fresh, oxygenated Krebs solution.
The method used to evoke neuromuscular contractions and relaxations of human isolated gastrointestinal 
tissues by EFS has been described70. In brief, strips (4–16 from each patient) were mounted in 10 ml tissue baths 
containing Krebs solution at 37°, gassed with 5% CO2 in O2. Changes in muscle tension were recorded in a similar 
manner to the mouse experiments except that the tissues were suspended under 2 g tension and EFS applied using 
the parameters of 50 V (c. 200 mA), 0.5 ms bipolar pulse duration, 5 Hz, given for 10 s, every 1 min with the bath-
ing solution changed every 15 min until consistency of responses to EFS was achieved; this has previously been 
shown to evoke clear, apparently submaximal responses which represent each of the relaxation and contraction 
phenotypes observed throughout a range of frequencies studied44,70. Single concentrations of drugs were applied 
to each muscle strip and their effects determined by measuring at least three EFS-induced responses at a given 
time-point; changes were expressed as a percentage change from the mean pre-treatment EFS-induced responses. 
Receptor antagonists and inhibitors were applied for 30 min prior to agonist application. Changes in baseline 
tension were also expressed as a % of the pre-treatment EFS-induced contraction. The effects of treatments on 
carbachol-induced contractions were performed after first obtaining consistent responses to 1 μ M carbachol (the 
concentration causing ~50% of maximum contraction to carbachol; 5 min contact, repeated at 15 min intervals) 
before addition of the drug 15 min before the last application of carbachol.
Statistical analysis of studies using native tissues. Data are expressed as means ± SD (cell-based 
assays), medians and ranges (patient characteristics) or as the mean ± standard error of the mean (native tissue 
experiments) with n values indicating the number of patients or animals. EC50 and Emax values were obtained from 
3 parameter agonist-response curves plotted using GraphPad Prism versions 5.0–6.07; Emax values are reported as 
mean ± standard error. Unpaired Student’s t tests or two way ANOVA models followed by Bonferroni’s multiple 
comparison tests were used to analyse independent or inter-dependent effects of drugs. The differences between 
the best fit parameters obtained from the curves were compared using extra sum of squares F tests. P < 0.05 was 
considered to represent statistical significance.
Drugs used in native tissue studies. These were freshly prepared prior to use. Carbachol, atropine, 
L-NAME (Nω-nitro-L-arginine methyl ester hydrochloride), propranolol, phentolamine (each from Sigma, UK) 
and tetrodotoxin (Tocris, UK) were each dissolved in distilled water (dH2O). Asimadoline (generous gift from 
Tioga Inc, USA), ICI204448 and nor-binaltorphimine (both Tocris, UK) were dissolved to 10 mM in DMSO.
Opioid receptor gene, kappa (OPRK) alignment and tertiary structural analysis. ClustalX 
was used to align the human, rat and mouse OPRK sequences (uniprot accessions P41145, P34975 and P33534 
respectively). Alignments were visualised and annotated for important structural residues using Jalview (www.
jalview.org). A homology modelled structure of human OPRK1 was obtained from the PDB database (http://
www.ebi.ac.uk/pdbe/; PDB id 2a0d). C-terminal rodent residue substitutions were modelled using Swiss PDB 
viewer (http://spdbv.vital-it.ch/).
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